Comparative Pharmacology
Head-to-head clinical analysis: CALCIPARINE versus HEPARIN SODIUM 10 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: CALCIPARINE versus HEPARIN SODIUM 10 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
CALCIPARINE vs HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unfractionated heparin (UFH) potentiates antithrombin III (ATIII) activity, leading to inhibition of factor Xa and thrombin (factor IIa). It also binds to heparin cofactor II, inhibits platelet aggregation, and increases vascular permeability.
Heparin binds to antithrombin III, accelerating the inactivation of thrombin (factor IIa) and factor Xa, thereby inhibiting coagulation.
5000 IU subcutaneously twice daily for prophylaxis; 5000 IU intravenous bolus followed by 800-1000 IU/hour continuous intravenous infusion for treatment.
For therapeutic anticoagulation, administer intravenous bolus of 80 units/kg followed by continuous infusion at 18 units/kg/hour, adjusted to maintain aPTT 1.5-2.5 times control. For prophylaxis, 5,000 units subcutaneously every 8-12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5 hours (subcutaneous) after a 5000 IU dose. With therapeutic doses (e.g., 15,000 IU/24h), half-life may prolong to 2-3 hours. Clinical context: Half-life is dose-dependent and increases with heparin clearance saturation.
Mean terminal half-life 1.5 hours (range 1-2 hours) at therapeutic doses; dose-dependent (nonlinear) due to saturable clearance; prolonged in renal impairment (up to 3-6 hours) and hepatic disease.
Primarily renal, with 40-60% of the dose excreted unchanged in urine. Minor biliary/fecal elimination (<10%).
Primarily hepatic and reticuloendothelial system metabolism; renal excretion of metabolites accounts for <50% of clearance; minimal biliary/fecal elimination.
Category C
Category A/B
Anticoagulant
Anticoagulant